Delcath Systems, Inc.

As of October 17, 2025, Delcath Systems, Inc. is considered overvalued with a valuation grade of expensive, indicated by a high Price to Book Value of 7.11, an EV to Sales ratio of 9.50, and a P/E ratio of 68.06, significantly exceeding its peers.

As of October 17, 2025, Delcath Systems, Inc. is considered overvalued with a P/E ratio of 68.06, a price-to-book value of 7.11, and an EV to sales ratio of 9.50, significantly higher than industry peers like iCAD, Inc. and Eargo, Inc.

As of August 12, 2025, the trend has shifted to mildly bearish due to bearish weekly MACD and KST indicators, despite mixed signals across timeframes and a bullish monthly view.

As of August 6, 2025, Delcath Systems, Inc. is considered overvalued with a valuation grade of expensive, reflected by its high Price to Book Value of 7.11, EV to Sales ratio of 9.50, and P/E ratio of 68.06, significantly exceeding industry benchmarks and indicating poor performance relative to peers and the S&P 500.

As of June 18, 2025, the trend is mildly bullish due to daily moving averages and monthly KST, but caution is advised as weekly MACD and Dow Theory show mild bearishness, creating mixed signals.

As of March 2022, the management team of Delcath Systems, Inc. includes Dr. Roger Stoll (Non-Executive Independent Chairman), Mr. Gerard Michel (CEO and Director), and several Independent Directors: Dr. Gilad Aharon, Ms. Elizabeth Czerepak, Mr. Steven Salamon, and Mr. John Sylvester. This team provides executive leadership and governance for the company.

Delcath Systems, Inc. is a late-stage clinical development company focused on liver cancer treatments, with recent net sales of $20 million and a market cap of $509.51 million. The company is currently not profitable, with a net profit of $1 million reported for March 2025.

As of Jun 18, Delcath Systems, Inc. has a market capitalization of 509.51 million, with net sales of 53.85 million and a net profit of -14.21 million over the last four quarters. The company reported shareholder's funds of 68.75 million and total assets of 76.59 million as of Dec 24.